Search this site

Egypt Signs Strategic Tripartite Partnership to Build an Integrated Medical Manufacturing Ecosystem for Regional & Global Markets Engineer Mohamed Shimi, Minister of Public Business Sector, witnessed the signing of a major tripartite partnership between Dawah Holding International (Egypt), Dawah Pharma LLC (USA), and QG Medical Devices (Qatar-Germany) at the Ministry’s headquarters in the New Administrative Capital. The ceremony was attended by the heads of the Egyptian Drug Authority (EDA) and the Unified Procurement Authority, along with senior company representatives. This agreement aims to establish a fully integrated ecosystem for the manufacturing and supply of pharmaceuticals and medical devices, reinforcing Egypt’s position as a regional hub serving Arab and global markets. It supports national efforts to localize advanced medical technologies, expand exports, and enhance regional health security The Minister emphasized that the partnership represents a key step toward modernizing the pharmaceutical industry within state-affiliated companies, supporting Egypt’s Vision 2030 to boost industrial investment, strengthen pharmaceutical security, and enhance the global competitiveness of Egyptian and Arab products Dr. Ali El-Ghamrawy, Chairman of the EDA, highlighted the Authority’s role as a strategic partner in fostering investment and localizing medical supplies manufacturing to build a strong national industry capable of competing globally Dr. Hisham Sayed Sitet, Chairman of the Unified Procurement Authority, stated that the agreement supports the creation of a unified Arab medical supply system offering high quality products at competitive prices From the private sector side, Dr. Hossam Abdel-Maksoud, Chairman and CEO of Dawah Pharma LLC, described the partnership as “a foundation for an Arab-international healthcare alliance that drives innovation and knowledge exchange.” Mr. Fahd Abdullah Malik, Vice Chairman of QG Medical Devices, said the collaboration opens new opportunities for medical manufacturing cooperation between Qatar, Egypt, and the U.S The partnership reflects a shared vision of “Health Without Borders”, with industrial and scientific projects that expand across Egypt, Africa, and the Arab region aligned with Egypt’s and Qatar’s national development goals

GYPTO Pharma Signs Preliminary Agreement with Mozambique Government to Establish Regional Pharmaceutical Distribution Hub Dawah Gypto has signed a preliminary agreement with the Government of Mozambique to establish a regional pharmaceutical distribution hub and a packaging facility for liquid and semi-liquid medications This strategic step reinforces the company’s presence in the Southern African region, enhancing access to high-quality and affordable medicines within SADC countries. The collaboration reflects strong confidence in Dawah Gypto’s capabilities and its commitment to supporting sustainable healthcare development. The project will contribute to improving medicine availability, creating local job opportunities, and advancing technology transfer in the pharmaceutical sector. Dawah Gypto continues to expand its footprint across Africa with a clear vision to elevate healthcare standards and deliver life-saving treatments to communities across the continent.

Egypt’s Gypto Pharma (Medicine City) and US-based Dawa Pharmaceuticals signed a strategic alliance agreement aimed at strengthening Egypt’s pharmaceutical industry and achieving US Food and Drug Administration (FDA) qualification for Gypto Pharma’s facilities. Egyptian Prime Minister Mostafa Madbouly witnessed the signing ceremony at the government headquarters in the New Administrative Capital. The event was attended by senior officials including Minister of Planning and International Cooperation Rania Al-Mashat, Minister of Investment Hassan El Khatib, presidential health advisor Mohamed Awad Tag El-Din, the heads of the Egyptian Drug Authority (EDA) and the Unified Procurement Authority (UPA), US Ambassador to Cairo Herro Mustafa Garg, and Qatari Ambassador Tariq Ali Faraj Al-Ansari. The agreement was signed by Amr Mamdouh, Chairperson of Gypto Pharma, and Hossam Abdel Maksoud, Chairperson and CEO of Dawa Pharmaceuticals. Prime Minister Madbouly stated that Egypt’s pharmaceutical industry is a “vital field for new trade and investment and mutual growth between the United States and Egypt” and receives significant attention from President Abdel Fattah Al-Sisi. He noted the president’s support for localising vital industries, including pharmaceuticals, and seeking new export markets such as the United States. Madbouly emphasised the partnership’s importance in bringing “advanced American equipment and expertise to Egypt” and supporting efforts to gain FDA accreditation. He said this would enhance the Egyptian pharmaceutical industry’s regional and international standing and confirm its readiness to compete globally “The economic partnership between Egypt and the United States continues to grow,” Madbouly said, adding that the agreement is “another example of our two countries’ cooperation to create shared economic prosperity for both countries.” US Ambassador Garg highlighted the agreement’s significance: “The critical element in this historic agreement between Dawa Pharmaceuticals and Gypto Pharma is the provision of advanced American equipment and technology alongside know-how to expand the production of Egyptian medicines throughout Africa and the Middle East.” She added that the partnership underscores “the strength of our bilateral economic relationship and the shared prosperity it brings to both Egypt and the United States.” Mamdouh of Gypto Pharma called the partnership an “important step towards achieving the company’s vision of being a regional hub for the pharmaceutical industry,” leveraging its existing infrastructure. He noted recent successes, including partnerships with seven international firms for joint manufacturing and technology transfer, and the launch of essential medicines. “This alliance aims to invest in developing Gypto Pharma’s production capabilities, adding new lines and modern systems according to the requirements of the US Food and Drug Administration (FDA), and qualifying for export to the US market,” Mamdouh said. He stressed the alignment with state goals of encouraging investment, localising industries, and boosting exports. Abdel Maksoud of Dawa Pharmaceuticals expressed pride in the partnership, calling it a “pivotal step towards supporting innovation efforts and industrial integration in the pharmaceutical industry field.” He described Gypto Pharma as a “strategic partner with advanced industrial capabilities, and a clear vision.” Abdel Maksoud affirmed Dawa’s commitment to “transferring the necessary technical expertise and know-how to support Gypto Pharma in obtaining the qualification of the US Food and Drug Administration (FDA),” enabling US market entry and enhancing local manufacturing to global standards The statement noted the agreement aims to enhance bilateral trade and investment in pharmaceutical innovation, improve products for consumers in both countries, and boost the value of their respective biopharmaceutical industries

Current Market The sterile injectables market is experiencing significant growth, driven by factors such as the increasing prevalence of chronic diseases, technological advancements in drug delivery systems, and a rising demand for biologics. Global Market Outlook Market Size and Growth: The global sterile injectables market was valued at approximately USD 109.1 billion in 2024 and is projected to reach USD 230.5 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.8% during the forecast period. Business Research Insights Regional Insights North America: This region dominates the market, accounting for a significant share of global revenue. Factors contributing to this dominance include a well-established healthcare infrastructure, high adoption of advanced technologies, and an increasing prevalence of chronic diseases. Market Research Future Asia Pacific: The market in this region is expected to witness substantial growth, driven by an increasing prevalence of chronic diseases and changing lifestyles. Market Research Future Therapeutic Applications The sterile injectables market encompasses a wide range of therapeutic applications, including oncology, diabetes, cardiovascular diseases, central nervous system disorders, infectious disorders, and musculoskeletal conditions. The oncology segment is particularly significant, driven by the rising incidence of cancer and the development of innovative oncology drugs. Business Research Insights Market Drivers Rising Prevalence of Chronic Diseases: The increasing incidence of conditions such as cancer, diabetes, and cardiovascular diseases necessitates effective treatments, thereby driving the demand for sterile injectables. Market Research Future Technological Advancements: Innovations in drug delivery systems, such as prefilled syringes and auto-injectors, have improved the convenience, safety, and efficacy of sterile injectable administration, further propelling market growth. Strategic Market Research Challenges Despite the positive outlook, the market faces challenges, including stringent regulatory requirements, high manufacturing costs, and the need for maintaining strict sterility standards throughout the production process. Pharmaceutical Technology Conclusion The sterile injectables market is poised for significant growth, offering substantial opportunities for companies operating in this space. A thorough understanding of market dynamics, regional trends, and therapeutic demands is essential for capitalizing on the potential presented by this expanding market.

Contact Us for an EB5 or E2 Visa Investment Opportunity Submit

Mathew Cherian Chief Operating Officer Mathew Cherian is the Chief Operating Officer and Co-Founder of the company, bringing more than 34 years of international experience in the pharmaceutical industry across the United States and Europe. Before co-founding the organization, Mr. Cherian served as Director and Senior Fellow at a leading global pharmaceutical company. During his tenure, he played a key role in early stage product development and successfully coordinated research efforts across multiple global Pfizer sites. His extensive expertise in complex pharmaceutical products continues to support the development of innovative therapies across several therapeutic areas. Mr. Cherian is a recognized expert in drug device combination products and is a leader in advancing differentiated drug delivery systems, contributing to the development of high-value, advanced pharmaceutical solutions. He holds a Ph.D. in Chemical Engineering from the University of Rhode Island and is an inventor with multiple patents. Widely regarded as a thought leader in the industry, he regularly speaks at global pharmaceutical forums and serves on the Executive Committee of the International Pharmaceutical Society. enhance community well being.

Pipeline Dawah Pharmaceuticals Inc. is advancing global healthcare through a robust pipeline of essential drugs in collaboration with top-tier international Contract Manufacturing Organizations (CMOs). By leveraging strategic overseas partnerships, we ensure the efficient delivery of FDA-compliant drugs that address critical therapeutic needs across a wide range of disease states. Read More Sterile Injectables Antipsychotics Help manage both chronic and acute mental health disorders to stabilize patients Paralytics Used to facilitate anesthesia and ensure patient immobilization during surgery or critical care Antibiotics Target and treat severe bacterial infections, including resistant strains Oncology Drugs Provide innovative and life-saving treatments for various types of cancer Antifungals Treat systemic and invasive fungal infections effectively. Ophthalmics Anti-inflammatory Agents: Reducing inflammation in ocular diseases. Antibiotic-Corticosteroid Combinations: Treating bacterial infections with concurrent inflammation. Antihistamines: Providing relief from allergic conjunctivitis and related ocular allergies. Bags and (TPN) Pain Management: Offering intravenous acetaminophen for effective pain and fever control. Critical Care Solutions: Including dopamine and electrolytes for emergency and intensive care applications. Nutritional Support: High-use TPN formulations for patients with impaired oral intake. Overseas Partnerships Dawah Pharmaceuticals has meticulously evaluated over 30 global CMOs and strategically partnered with two industry leaders based overseas. These partnerships are integral to our operations Optimize manufacturing costs with contributions of the sterile production cost by our selected CMOs. Activities Provided by CMOs Comprehensive Development: Formulation, process design, and analytical testing. Regulatory Preparedness: Manufacturing registration batches and compiling FDA dossiers. Stability Testing: Ensuring efficacy and safety over extended periods. Our partnerships empower Dawah Pharmaceuticals to maintain agility while delivering high-quality, FDA-compliant drugs to address critical healthcare needs. By continuously assessing market trends and patient requirements, we are committed to expanding our pipeline and improving global access to essential medications. Commitment to Excellence Here is a list of the drugs we plan to bring to the U.S. market via JV, along with their indications and projected launch years. 2026–2027 Bacterial infections (oral antibiotic) 2028 Type 2 diabetes, weight management 2028–2029 Acute heart failure, cardiac stress testing 2028–2029 Edema, congestive heart failure, hypertension 2028–2029 Short-term pain relief (injectable NSAID) 2028–2029 Gallstone dissolution, primary biliary cholangitis 2027–2028 Antiplatelet (cardiovascular diseases) 2028–2029 Sedation in intensive care and surgical settings 2028–2029 Induction of general anesthesia 2028–2029 Short-term pain relief (injectable NSAID) 2028–2029 Alzheimer’s disease 2031 Chemotherapy, autoimmune diseases (oncology)

توماس إنغالينيرا نائب الرئيس للعمليات يشغل الدكتور توماس إنغالينيرا منصب نائب الرئيس للعمليات، ويملك أكثر من 40 عامًا من الخبرة في البحث والتطوير الدوائي، مع تخصص في أشكال الجرعات القابلة للحقن. يقدم الدكتور إنغالينيرا القيادة التقنية والعلمية عبر برامج تطوير الأدوية، داعمًا المشاريع منذ مرحلة ما قبل التكوين وحتى الإنتاج التجاري الكامل. وقد شغل مناصب عليا في مؤسسات عالمية رائدة، بما في ذلك Pharmaceutics International، وBioCryst Pharmaceuticals، وParenta Pharmaceuticals، وAAI Pharma، وGenzyme، وBurroughs Wellcome، وA.H. Robins. يحمل شهادة بكالوريوس العلوم في الصيدلة ودكتوراه في الصيدلة من جامعة فيرجينيا كومنولث. وبالإضافة إلى دوره التنفيذي، يعمل الدكتور إنغالينيرا عضوًا في مجموعة الاستشارات التقنية لمؤسسة بيل وميليندا غيتس، مساهماً بخبراته في المبادرات الصحية العالمية.